Literature DB >> 6179500

Lack of correlation between impaired interferon production and natural killer activity of lymphocytes in multiple sclerosis.

I Stöger, M Tálas, M Benczúr, E Gyódi, G G Petrányi, G Pálffy, B Kotsy.   

Abstract

The ability of lymphocytes from patients with multiple sclerosis (MS) to produce Interferon (IFN-alpha) in response to Newcastle Disease Virus (NDV) was studied in vitro. The correlation between individual IFN-alpha titers and natural killer (NK) cell activity and the presence of HLA system antigens associated with MS (B-7 and DRW-2) was also investigated. Lymphocytes from MS patients showed a significantly impaired capacity to synthesize IFN-alpha in vitro when compared to lymphocytes from healthy donors (mean titers: 85.9 I.U. and 268.2 I.U., respectively). Marked differences in IFN-alpha titers were observed in the group of MS patients. The production of IFN-alpha by the patients' lymphocytes did not correlate with either the activity of NK cells or with their stimulation by exogenous IFN-alpha. There was also no correlation between IFN-alpha production by lymphocytes from MS patients and the presence or absence of B-7 and DRW-2 antigens.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179500     DOI: 10.1007/BF01314877

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  22 in total

1.  INFECTIVE AGENTS AND MULTIPLE SCLEROSIS.

Authors:  C A ROSS; J A LENMAN; C RUTTER
Journal:  Br Med J       Date:  1965-01-23

Review 2.  Mechanisms of activation of human natural killer cells against tumor and virus-infected cells.

Authors:  D Santoli; H Koprowski
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  Rickettsial and viral antibodies in multiple sclerosis.

Authors:  C A ROSS
Journal:  Br Med J       Date:  1962-06-02

4.  The formation of interferon during acute respiratory virus infection of volunteers.

Authors:  A A Smorodintsev; A S Beare; M L Bynoe; B Head; D A Tyrrell
Journal:  Arch Gesamte Virusforsch       Date:  1971

5.  Enhancement of virus multiplication and interferon production by cortisone in ocular herpesvirus infection.

Authors:  J O Oh
Journal:  J Immunol       Date:  1970-06       Impact factor: 5.422

6.  A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

7.  Correlation between effector lymphocytes in natural and antibody-mediated cytotoxicity.

Authors:  M Benczur; G Györffy; T Garam; M Varga; G Medgyesi; M Sándor; G G Petranyi
Journal:  Immunobiology       Date:  1979-09       Impact factor: 3.144

8.  Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis.

Authors:  D Santoli; W Hall; L Kastrukoff; R P Lisak; B Perussia; G Trinchieri; H Koprowski
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Measles antibody in serum of multiple sclerosis patients, their children, siblings and parents.

Authors:  T Ammitzboll; J Clausen
Journal:  Acta Neurol Scand       Date:  1972       Impact factor: 3.209

10.  Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor.

Authors:  M Benczur; G G Petrányl; G Pálffy; M Varga; M Tálas; B Kotsy; I Földes; S R Hollán
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

View more
  3 in total

1.  Subsets of T lymphocytes in relation to T lymphocyte function in multiple sclerosis.

Authors:  J C Craig; S A Hawkins; M W Swallow; J A Lyttle; V H Patterson; J D Merrett; M Haire
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

2.  Reduced killer cell activity of lymphocytes from patients with asbestosis.

Authors:  M Kubota; S Kagamimori; K Yokoyama; A Okada
Journal:  Br J Ind Med       Date:  1985-04

3.  Interferon production in primary immunodeficiencies.

Authors:  P M Matricardi; M R Capobianchi; R Paganelli; J Facchini; M C Sirianni; R Seminara; F Dianzani; F Aiuti
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.